CHU UCL Namur
- Address
- Avenue Docteur Gaston Therasse 1, 5530 Yvoir, Belgium
Cardiovascular Diseases
At CHU UCL Namur, investigators are assessing innovative preventive strategies to lower the incidence of heart attacks and strokes in high‑risk patients, with a focus on the novel agent inclisiran.
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Evaluation of major adverse cardiovascular events
- Risk‑reduction therapies in primary prevention
The goal is to provide safer, more effective options for long‑term cardiovascular health and to reduce the burden of disease in the community.
Hemic and Lymphatic Diseases
The oncology department runs multiple studies aimed at improving outcomes for malignant blood‑forming and lymphatic disorders, including trials of the bispecific antibody odronextamab.
- B‑Cell Non‑Hodgkin’s Lymphoma
- Follicular lymphoma
- Classical Hodgkin Lymphoma
- Relapsed or refractory lymphomas
By comparing new immunotherapies with standard chemotherapy, these studies seek to extend survival and enhance quality of life for patients with challenging lymphoid cancers.
Neoplasms
A comprehensive cancer program at CHU UCL Namur explores advanced treatments for solid tumors, featuring the selective estrogen receptor degrader camizestrant and the checkpoint inhibitor pembrolizumab.
- ER+/HER2‑ negative early breast cancer
- Muscle‑invasive bladder cancer
- Other solid tumor investigations
The trials aim to reduce disease recurrence, improve surgical outcomes, and offer new therapeutic options for patients with early‑stage and locally advanced cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 7 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Regeneron Pharmaceuticals Inc.2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU UCL Namur
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 7 | Unknown | 2020-01-20 | 2024-02-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.